FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+4.27%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$772M
AUM Growth
+$772M
(+20%)
Cap. Flow
+$98.2M
Cap. Flow
% of AUM
12.72%
Top 10 Holdings %
Top 10 Hldgs %
80.5%
Holding
18
New
3
Increased
5
Reduced
–
Closed
1
Top Buys
| 1 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$32.2M |
| 2 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$22.4M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$18.6M |
| 4 |
Scholar Rock
SRRK
|
$15.9M |
| 5 |
Enliven Therapeutics
ELVN
|
$10.2M |
Top Sells
| 1 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$10.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.17B
| $89M | 11.53% | 2,048,647 | – | – |
|
2
Axsome Therapeutics
AXSM
$6.05B
| $85.1M | 11.02% | 815,176 | – | – |
|
|
3
Enliven Therapeutics
ELVN
$1.2B
| $74.5M | 9.65% | 3,711,444 +508,646 | +16% | +$10.2M |
|
|
4
Scholar Rock
SRRK
$3.14B
| $64.6M | 8.37% | 1,824,031 +450,000 | +33% | +$15.9M |
|
5
Spyre Therapeutics
SYRE
$996M
| $60.2M | 7.79% | 4,018,101 | – | – |
|
6
Nuvalent
NUVL
$5.52B
| $55.5M | 7.19% | 727,563 | – | – |
|
7
Dianthus Therapeutics
DNTH
$759M
| $50.4M | 6.53% | 2,707,191 +6,500 | +0.2% | +$121K |
|
|
8
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $49.1M | 6.36% | 1,772,839 +670,591 | +61% | +$18.6M |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $48.4M | 6.27% | 3,459,913 +14,100 | +0.4% | +$197K |
|
10
Cogent Biosciences
COGT
$1.69B
| $44.7M | 5.79% | 6,225,641 | – | – |
|
|
ORKA
11
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $37.8M | 4.9% | 3,371,922 | – | – |
|
|
JBIO
12
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $32.2M | 4.17% | +3,220,368 | New | +$32.2M |
|
|
CBIO
13
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $22.4M | 2.9% | +1,387,866 | New | +$22.4M |
|
14
Astria Therapeutics
ATXS
$349M
| $19.1M | 2.47% | 3,554,129 | – | – |
|
|
ZBIO
15
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $18.3M | 2.38% | 1,892,806 | – | – |
|
16
Inhibikase Therapeutics
IKT
$134M
| $11.9M | 1.55% | 6,125,000 | – | – |
|
17
CytomX Therapeutics
CTMX
$336M
| $8.85M | 1.15% | +3,896,582 | New | +$8.85M |
|
|
BCAX
18
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| – | – | -784,170 | Closed | -$10.2M |
|